Press Releases

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Paris, November 5th 2019 – Acticor Biotech, a clinical stage biotechnology company dedicated to the acute phase of thrombo-embolic diseases, including stroke, announces its participation to the BOOSTER consortium, dedicated to personalized medicine for the management of stroke in emergency situations. Led by Professor Mikael Mazighi from Paris University, who is neurologist at Lariboisière Hospital […]
Read more

Acticor Biotech raises €15.3M in a Series B financing

Paris, October 16, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, today announced that it has completed a €15.3 million Series B round of financing from European and Asian investors. This new funding will enable the company to finance its first […]
Read more

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Paris, July 31, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, announces the signature of an Asset Transfer and Licensing agreement covering a development and commercialisation collaboration agreement with CMS Medical Limited as well as an investment agreement with CMS Medical […]
Read more

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Paris, April 25th, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, has discussed with the European Medicines Agency (EMA) the development of its drug candidate, ACT017. This meeting follows the completion of the first-in-human study in January 2018 which provided preliminary […]
Read more
Page 1 of 41234